A Phase 2 interventional study of ABT-981 and Placebo for ABT-981 in Erosive Hand Osteoarthritis, sponsored by AbbVie. Completed. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-11.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of ABT-981 to placebo in subjects with erosive hand osteoarthritis.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
This study's enrollment of 132 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnosis of one or more of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
Biological: Placebo for ABT-981
ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
Biological: ABT-981
ABT-981 administered by subcutaneous injection
Also known as: lutikizumab
Placebo for ABT-981 administered by subcutaneous injection
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. Last Observation Carried Forward (LOCF): Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
Time frame: Week 0 (Baseline), Week 16
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Each Visit
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Physical Function Subdomain Score: Change From Baseline to Each Visit
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The physical function subdomain score ranges from 0 to 90; lower scores indicate better status. A decrease in the physical function subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Stiffness Subdomain Score: Change From Baseline to Each Visit
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The stiffness subdomain score ranges from 0 to 10; lower scores indicate better status. A decrease in the stiffness subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Total Score: Change From Baseline to Each Visit
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The total score ranges from 0 to 150; lower scores indicate better status. A decrease in the total score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Participant Assessment of Index Hand Pain Intensity Using Numeric Rating Scale (NRS-11): Change From Baseline to Each Visit
Participants rated the pain intensity of each hand during the previous 48 hours using an 11-point scale (NRS-11). The change from baseline to each visit in NRS-11 in the index hand (the hand with the most disease) are presented. Scores range from 0 to 10 points, with higher scores indicating greater pain intensity. A decrease in the NRS-11 score represents a decrease in pain intensity.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Patient Global Assessment of Hand Osteoarthritis (OA) Status by NRS-11: Change From Baseline to Each Visit
Participants were asked how much they were affected by hand OA by responding to the question "Considering all the ways your hand OA affects you, how have you been during the last 48 hours?" using an 11-point scale (NRS-11). Scores range from 0 to 10 points, with higher scores indicating greater effect of hand OA on the participant. A decrease in the NRS-11 score represents an improvement the effect of hand OA on the participant.
Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
| Milestone | Placebo | ABT-981 |
|---|---|---|
| Started | 67 | 64 |
| Completed | 61 | 49 |
| Not completed | 6 | 15 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Lack of efficacy | 4 | 4 |
| Withdrew: Withdrew consent | 0 | 4 |
| Withdrew: Other | 1 | 3 |
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. Last Observation Carried Forward (LOCF): Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16 | -10.74 (-15.433 to -6.045) | -9.22 (-13.798 to -4.645) |
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -3.25 (-7.058 to 0.550) | -3.27 (-6.983 to 0.438) |
| Week 4 | -5.01 (-9.144 to -0.885) | -4.26 (-8.280 to -0.237) |
| Week 8 | -8.90 (-13.065 to -4.744) | -6.44 (-10.488 to -2.384) |
| Week 12 | -8.31 (-12.593 to -4.030) | -5.64 (-9.809 to -1.469) |
| Week 16 | -10.74 (-15.443 to -6.045) | -9.22 (-13.798 to -4.645) |
| Week 20 | -7.28 (-11.969 to -2.591) | -8.37 (-12.941 to -3.807) |
| Week 26 | -8.76 (-13.782 to -3.737) | -10.37 (-15.264 to -5.481) |
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The physical function subdomain score ranges from 0 to 90; lower scores indicate better status. A decrease in the physical function subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -6.23 (-13.098 to 0.630) | -4.79 (-11.440 to 1.861) |
| Week 4 | -8.43 (-15.879 to -0.974) | -7.04 (-14.249 to 0.177) |
| Week 8 | -14.25 (-21.729 to -6.763) | -8.97 (-16.211 to -1.725) |
| Week 12 | -12.54 (-20.140 to -4.947) | -8.53 (-15.887 to -1.182) |
| Week 16 | -17.18 (-24.938 to -9.431) | -14.64 (-22.142 to -7.133) |
| Week 20 | -11.50 (-19.415 to -3.584) | -12.53 (-20.189 to -4.867) |
| Week 26 | -14.25 (-22.523 to -5.978) | -16.39 (-24.402 to -8.388) |
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The stiffness subdomain score ranges from 0 to 10; lower scores indicate better status. A decrease in the stiffness subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -0.74 (-1.692 to 0.215) | -0.96 (-1.877 to -0.036) |
| Week 4 | -0.98 (-1.937 to -0.028) | -1.24 (-2.163 to -0.321) |
| Week 8 | -1.51 (-2.535 to -0.493) | -1.43 (-2.412 to -0.441) |
| Week 12 | -1.65 (-2.706 to -0.599) | -1.23 (-2.244 to -0.211) |
| Week 16 | -1.76 (-2.885 to -0.633) | -1.61 (-2.695 to -0.522) |
| Week 20 | -1.34 (-2.515 to -0.169) | -1.85 (-2.986 to -0.722) |
| Week 26 | -1.94 (-3.017 to -0.859) | -2.45 (-3.492 to -1.410) |
The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The total score ranges from 0 to 150; lower scores indicate better status. A decrease in the total score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -10.01 (-21.037 to 1.019) | -8.85 (-19.545 to 1.835) |
| Week 4 | -14.06 (-26.185 to -1.930) | -12.18 (-23.928 to -0.439) |
| Week 8 | -24.52 (-36.660 to -12.373) | -16.65 (-28.406 to -4.886) |
| Week 12 | -22.29 (-34.714 to -9.873) | -15.15 (-27.181 to -3.124) |
| Week 16 | -29.37 (-42.469 to -16.264) | -25.12 (-37.808 to -12.429) |
| Week 20 | -19.68 (-32.894 to -6.458) | -22.33 (-35.128 to -9.526) |
| Week 26 | -24.73 (-38.636 to -10.820) | -28.99 (-42.461 to -15.523) |
Participants rated the pain intensity of each hand during the previous 48 hours using an 11-point scale (NRS-11). The change from baseline to each visit in NRS-11 in the index hand (the hand with the most disease) are presented. Scores range from 0 to 10 points, with higher scores indicating greater pain intensity. A decrease in the NRS-11 score represents a decrease in pain intensity.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -0.62 (-1.550 to 0.320) | -0.69 (-1.613 to 0.228) |
| Week 4 | -1.18 (-2.163 to -0.195) | -1.06 (-2.025 to -0.088) |
| Week 8 | -2.40 (-3.339 to -1.465) | -1.74 (-2.660 to -0.814) |
| Week 12 | -1.65 (-2.434 to -0.875) | -0.81 (-1.629 to 0.010) |
| Week 16 | -2.05 (-3.085 to -1.017) | -1.60 (-2.626 to -0.578) |
| Week 20 | -1.61 (-2.749 to -0.477) | -1.75 (-2.892 to -0.612) |
| Week 26 | -2.02 (-3.132 to -0.901) | -2.52 (-3.620 to -1.415) |
Participants were asked how much they were affected by hand OA by responding to the question "Considering all the ways your hand OA affects you, how have you been during the last 48 hours?" using an 11-point scale (NRS-11). Scores range from 0 to 10 points, with higher scores indicating greater effect of hand OA on the participant. A decrease in the NRS-11 score represents an improvement the effect of hand OA on the participant.
| units on a scale | Placebo | ABT-981 |
|---|---|---|
| Week 2 | -0.52 (-1.399 to 0.351) | -0.54 (-1.403 to 0.316) |
| Week 4 | -1.31 (-2.277 to -0.335) | -1.13 (-2.083 to -0.176) |
| Week 8 | -1.85 (-2.740 to -0.952) | -1.20 (-2.080 to -0.324) |
| Week 12 | -1.78 (-2.567 to -0.993) | -1.17 (-1.997 to -0.348) |
| Week 16 | -2.20 (-3.225 to -1.185) | -1.69 (-2.697 to -0.677) |
| Week 20 | -1.73 (-2.836 to -0.627) | -1.77 (-2.879 to -0.666) |
| Week 26 | -2.00 (-3.133 to -0.874) | -2.35 (-3.465 to -1.236) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 34 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/67 (3%) | 45/67 (67.2%) |
| ABT-981 | — | 2/64 (3.1%) | 49/64 (76.6%) |
| Event | Placebo | ABT-981 |
|---|---|---|
| FAECES DISCOLOUREDGastrointestinal disorders | 0/67 | 1/64 |
| HAEMOGLOBIN DECREASEDInvestigations | 0/67 | 1/64 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 0/67 | 1/64 |
| ACUTE CORONARY SYNDROMECardiac disorders | 1/67 | 0/64 |
| INVASIVE BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/67 | 0/64 |
| Event | Placebo | ABT-981 |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 17/67 | 13/64 |
| HEADACHENervous system disorders | 17/67 | 10/64 |
| BACK PAINMusculoskeletal and connective tissue disorders | 11/67 | 3/64 |
| NAUSEAGastrointestinal disorders | 2/67 | 8/64 |
| INJECTION SITE ERYTHEMAGeneral disorders | 0/67 | 7/64 |
| INJECTION SITE RASHGeneral disorders | 3/67 | 7/64 |
| INJECTION SITE REACTIONGeneral disorders | 3/67 | 7/64 |
| NEUTROPENIABlood and lymphatic system disorders | 0/67 | 6/64 |
| DIARRHOEAGastrointestinal disorders | 6/67 | 4/64 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 6/67 | 4/64 |
Modified intent-to-treat (mITT) population: all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | ABT-981 | Total |
|---|---|---|---|
| Mean | 65.8 ± 7.325 | 65.7 ± 8.132 | 65.7 ± 7.700 |
| Sex: Female, Male(Participants) | Placebo | ABT-981 | Total |
|---|---|---|---|
| Female | 58 | 53 | 111 |
| Male | 9 | 11 | 20 |
No study locations are listed for this record.
Ran from Mar 2015 to primary completion in Jul 2016, 16 months.
Results were first posted in Jul 2017, 1 year after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 16 months is close to that.
Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutikizumab